Related Experiment Video

Updated: Oct 4, 2025

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

8.1K

Combination therapy of first and third generation EGFR-TKIs for an advanced lung adenocarcinoma patient harboring

Yongxing Chen1, Chong Meng1, Kai Liu1

  • 1Department of Respiratory and Critical Care Medicine, Hainan General Hospital, Hainan Affiliated Hospital of Hainan Medical University, Haikou 570311, China.

Translational Cancer Research
|February 4, 2022
PubMed

Insights

Treatment resistance is common in advanced non-small cell lung cancer (NSCLC). A combination of osimertinib and icotinib effectively treated complex EGFR mutations, including T790M and EGFR amplification, in an NSCLC patient.

Area of Science:

  • Oncology
  • Pharmacology
  • Genetics

Background:

  • Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) have transformed advanced non-small cell lung cancer (NSCLC) treatment.
  • Acquired resistance to EGFR-TKIs is a significant clinical challenge, particularly with complex resistance mechanisms.
  • Current treatment strategies for complex resistance profiles remain limited.

Observation:

  • A patient with EGFR-mutated NSCLC developed combined T790M point mutation and EGFR amplification after first-line EGFR-TKI therapy.
  • This complex resistance profile presented a therapeutic challenge due to limited evidence for effective treatment strategies.

Findings:

  • The patient was treated with a combination of osimertinib and icotinib.
  • This combination therapy resulted in a significant clinical response and a clear molecular response.
  • This case provides clinical evidence for the efficacy of combining osimertinib and icotinib.

Implications:

  • The findings suggest that a combination of osimertinib and icotinib can be a safe and effective strategy for NSCLC patients with complex EGFR resistance mechanisms.
  • This approach may offer a new treatment option for patients who have developed resistance to standard EGFR-TKI therapies.
  • Further research is warranted to validate these findings in larger patient cohorts.
Keywords:
Case reportEGFR T790MEGFR amplificationicotinibosimertinib

More Related Videos

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

8.9K
A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds13:34

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds

Published on: April 6, 2016

10.3K

Related Concept Videos

Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.1K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.9K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
711
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.0K